Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for alleged violations of securities laws, specifically related to misleading statements regarding its Biologics License Application (BLA) for MOLBREEVI [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from March 7, 2024, to May 23, 2025, with a deadline for lead plaintiff appointments set for November 10, 2025 [2]. - The complaint alleges that Savara made false and misleading statements to the market, particularly regarding the adequacy of information provided in its BLA submitted to the FDA [2]. - It is claimed that the FDA was unlikely to approve Savara's BLA due to deficiencies in the information provided, which rendered the company's public statements materially misleading throughout the class period [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not a requirement for recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's status, with no cost or obligation to participate [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].